<DOC>
	<DOCNO>NCT00361049</DOCNO>
	<brief_summary>RATIONALE : Donor mesenchymal stem cell infusion may effective treatment acute chronic graft-versus-host disease cause donor stem cell transplant . PURPOSE : This phase I trial study side effect best dose donor mesenchymal stem cell treat patient acute chronic graft-versus-host disease undergo donor stem cell transplant .</brief_summary>
	<brief_title>Donor Mesenchymal Stem Cell Infusion Treating Patients With Acute Chronic Graft-Versus-Host Disease After Undergoing Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety donor mesenchymal stem cell ( MSC ) infusion patient acute extensive chronic graft-vs-host disease ( GVHD ) undergo HLA-identical sibling donor stem cell transplant . Secondary - Describe rate complete partial resolution GVHD MSCs use addition standard GVHD therapy . - Determine inflammatory cytokine level , lymphocyte subset , donor-reactive lymphocyte number blood patient acute GVHD prior therapy 7 14 day post-MSC therapy . - Determine donor MSCs engraft tissue inflame GVHD patient undergone gender-mismatched transplantation . OUTLINE : This multicenter , dose-escalation study donor mesenchymal stem cell ( MSC ) . Within 72 hour initiation medical therapy ( e.g. , corticosteroid , cyclosporine ) graft-vs-host disease , patient undergo donor MSC infusion 10-15 minute . Cohorts 3-6 patient receive escalate dos donor MSCs maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Blood sample obtain periodically examine immunoenzyme technique mixed lymphocyte reaction ( surrogate marker alloreactivity ) cytokine level ( TH1 [ i.e. , interleukin ( IL ) -2 interferon-gamma ] , TH2 [ i.e. , IL-10 IL-4 ] , inflammatory cytokine [ i.e. , tumor necrosis factor-alpha IL-1 ] ) . Tissue specimen examine CD45 immunohistochemistry fluorescent situ hybridization detect hematopoietic nonhematopoietic cell . After completion study treatment , patient follow periodically 1 year . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Developed acute graftvshost disease ( GVHD ) clinical grade IIIV extensive chronic GVHD undergoing HLAidentical sibling donor hematopoietic stem cell transplant indication , malignant nonmalignant Requires systemic immunosuppressive therapy systemic corticosteroid ( methylprednisone dose 2 mg/kg/day equivalent ) concurrent cyclosporine tacrolimus May enrol institutional allogeneic stem cell transplant protocol use either ablative nonmyeloablative preparative regimens No evidence relapse progressive malignant disease time GVHD PATIENT CHARACTERISTICS : Not pregnant Negative pregnancy test Creatinine clearance ≥ 20 mL/min Oxygen saturation ≥ 90 % room air No severe symptomatic restrictive obstructive lung disease respiratory failure require ventilator support No uncontrolled hypertension congestive heart failure , active angina pectoris require use nitrate , myocardial infarction within past 6 month , major ventricular arrhythmia cardiac failure require active treatment No significant organ dysfunction No active severe infection , include sepsis , pneumonia hypoxemia , persistent bacteremia , meningitis Fever without source allow PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>poor prognosis metastatic gestational trophoblastic tumor</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>